Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Heres what some studies show: it can reduce body weight by as much as 24% after 48 weeks and has a distinct dose-response effect
Individuals with PCOS (Polycystic Ovary Syndrome): Some women with PCOS experience insulin resistance, and GLP-1 medications can help improve insulin sensitivity and manage weight
Others bundle consultations, shipping, lab work, and ongoing provider access
Brain Res 1131:1
This study group was further divided in nuclear, cortical and diabetic cataract of 30 patients each
RetatrutideMounjaro (Tirzepatide)Wegovy (Semaglutide) Mechanism Triple (GLP-1 + GIP + Glucagon)Dual (GLP-1 + GIP)Single (GLP-1) Best weight loss in trials 30.3%22.5%20.7% Trial duration 104 weeks72 weeks72 weeks UK approval Not yetYes (Mounjaro)Yes (Wegovy) Injection frequency Once weeklyOnce weeklyOnce weekly One important caveat: the 30.3% figure comes from a 104-week trial, while the Mounjaro and Wegovy results are from 72-week trials
US$ 26.77
US$ 21.89
US$ 26.79
US$ 27.62
